Century Therapeutics (IPSC) shares were up more than 8% in recent Tuesday trading after the company reported Q3 results that beat market expectations.
The firm posted a Q3 net loss of $0.37 per diluted share, narrowing from $0.55 loss a year ago. Analysts polled by Capital IQ expected $0.45 loss per share.
Revenue for the quarter ended Sept. 30 was $791,000, compared with $148,000 a year earlier. Analysts polled by Capital IQ expected $550,000.
The company said it expects its funds will support operations into the H2 of 2026.
Price: 1.37, Change: +0.11, Percent Change: +8.33
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.